9-valent HPV Recombinant Vaccine (Hansenula Polymorpha)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug Name9-valent HPV Recombinant Vaccine (Hansenula Polymorpha)
Drug Alias Name9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPenile NeoplasmsAnus NeoplasmsNeoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Bovax Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Bovax Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPenile NeoplasmsAnus NeoplasmsPapillomavirus Infections +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A